Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2021; 16(01): 178-182
DOI: 10.4103/ajns.AJNS_230_20
Case Report

Glioblastoma occurring as second primary in a treated case of diffuse large B-Cell lymphoma

Pooja Gajaria
Department of Pathology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra
,
Asha Shenoy
Department of Pathology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra
,
Balaji Baste
Department of Pathology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra
,
Naina Goel
Department of Pathology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Glioblastoma as second primary malignancy (SPM) has been reported after prostate cancer, meningiomas, Hodgkin's lymphoma. We report an extremely rare case of glioblastoma as SPM, occurring after remission of diffuse large B-cell lymphoma (DLBCL). Fifty-year-old male presented with loss of consciousness followed by right-sided weakness. He was treated with chemotherapy for DLBCL of the cervical lymph nodes, 5 years back. Present scans revealed well-defined intra-axial lesion in the left parietal lobe, suggestive of central nervous system (CNS) involvement by lymphoma. Left parieto-occipital craniotomy was performed and microscopic examination revealed the tumor to be Glioblastoma, WHO Grade IV. The tumor cells were positive for glial fibrillary acid protein and negative for leucocyte common antigen. He was treated by radiotherapy and temozolomide. Pathologic examination is a must for CNS lesions. Had it not been for the biopsy, the patient would have been treated as a recurrence of CNS lymphoma by chemotherapy and would have probably succumbed.

Key-words:

Chemotherapy - diffuse large B-cell lymphoma - glioblastoma - non-Hodgkin's lymphoma

Financial support and sponsorship

Nil.




Publication History

Received: 12 May 2020

Accepted: 14 October 2020

Article published online:
16 August 2022

© 2021. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, LangerCE, et al. The epidemiology of glioma in adults: A “state of the science” review. Neuro Oncol 2014;16:896-913.
  • 2 Grace S, Muzaffar R, Veerapong J, Alkaade S, Poddar N, Phillips N, et al. Synchronous quadruple primary neoplasms: Glioblastoma, neuroendocrine tumor, schwannoma and sessile serrated adenoma in a patient with history of prostate cancer. Anticancer Res 2015;35:2121-7.
  • 3 Labuschagne JJ, Chetty D. Glioblastoma multiforme as a secondary malignancy following stereotactic radiosurgery of a meningioma: Case report. Neurosurg Focus 2019;46:E11.
  • 4 Marus G, Levin CV, Rutherfoord GS. Malignant glioma following radiotherapy for unrelated primary tumors. Cancer 1986;58:886-94.
  • 5 Joh D, Park BJ, Lim YJ. Radiation-induced glioblastoma multiforme in a remitted acute lymphocytic leukemia patient. J Korean Neurosurg Soc 2011;50:235-9.
  • 6 Brennan P, Coates M, Armstrong B, Colin D, Boffetta P. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia. Br J Cancer 2000;82:1344-7.
  • 7 Okines A, Thomson CS, Radstone CR, Horsman JM, Hancock BW. Second primary malignancies after treatment for malignant lymphoma. Br J Cancer 2005;93:418-24.
  • 8 Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006;107:108-15.
  • 9 Hemminki K, Lenner P, Sundquist J, Bermejo JL. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: Effect of diagnostic age and time since diagnosis. J Clin Oncol 2008;26:1850-7.
  • 10 Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin's lymphoma survivors: A meta-analysis. Ann Oncol 2011;22:1845-58.
  • 11 Warren S, Gates O. Multiple primary malignant tumors: A survey of the literature and statistical study. Am J Cancer 1932;16:1358-414.
  • 12 Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006;15:2020-6.
  • 13 Koubková L, Hrstka R, Dobes P, Vojtesek B, Vyzula R. Second primary cancers -- Causes, incidence and the future. Klin Onkol 2014;27:11-7.
  • 14 Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, et al. Cancer survivorship--genetic susceptibility and second primary cancers: Research strategies and recommendations. J Natl Cancer Inst 2006;98:15-25.
  • 15 Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program. Oncologist 2007;12:20-37.
  • 16 Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: Differences by lymphoma subtype. J Clin Oncol 2010;28:4935-44.
  • 17 Tao L, Foran JM, Clarke CA, Gomez SL, Keegan TH. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood 2014;123:3553-62.
  • 18 Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, et al. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Br J Haematol 2017;178:72-80.
  • 19 Montecucco A, Zanetta F, Biamonti G. Molecular mechanisms of etoposide. EXCLI J 2015;14:95-108.
  • 20 Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17:421-33.
  • 21 Talebian A, Goudarzi RM, Mohammadzadeh M, Mirzadeh AS. Vincristine-induced cranial neuropathy. Iran J Child Neurol 2014;8:66-8.
  • 22 Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 1992;6:163-73.
  • 23 Wardill HR, Mander KA, Van Sebille YZ, Gibson RJ, Logan RM, Bowen JM, et al. Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. Int J Cancer 2016;139:2635-45.
  • 24 Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 2012;107:207-12.
  • 25 Symss NP, Pande A, Chakravarthy MV, Ramamurthi R. Glioblastoma multiforme occurring in a child with acute lymphoblastic leukemia. J Pediatr Neurosci 2006;1:63-5.
  • 26 Pichon B, Champiat S, Aumont M, Loussouarn D, Frénel JS, Mahé MA, et al. Glioblastoma of the conus medullaris following treatment of Hodgkin's lymphoma: History of a case and literature review. OMICS J Radiol 2017;6:1-5.
  • 27 Van Ginderachter L, Cox T, Drijkoningen R, Achten R, Joosens E, Maes A, et al. Non-Hodgkin lymphoma after treatment with extended dosing temozolomide and radiotherapy for a glioblastoma: A case report. Case Rep Oncol 2013;6:45-9.
  • 28 Tunthanathip T, Kanjanapradit K, Ratanalert S, Phuenpathom N, Oearsakul T, Kaewborisutsakul A. Multiple, primary brain tumors with diverse origins and different localizations: Case series and review of the literature. J Neurosci Rural Pract 2018;9:593-607.